Silver Book Fact

Use of a monocolonal antibody with adjuvant chemotherapy in HER2+ individuals with operable cancer was associated with a 33 percent reduction in risk of death.

Romond, E, E Perez, J Bryant, V Suman, C Geyer, N Davidson, et al. Tastuzumab plus Adjuvant Chemotherapy for Operable HER-2 Positive Breast Cancer. NEJM. 2005; 353: 1673-84. http://www.nejm.org/doi/full/10.1056/NEJMoa052122

Reference

Title
Tastuzumab plus Adjuvant Chemotherapy for Operable HER-2 Positive Breast Cancer
Publication
NEJM
Publication Date
2005
Authors
Romond, E, E Perez, J Bryant, V Suman, C Geyer, N Davidson, et al.
Pages
1673-84
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • 5-Year Relative Survival Rates for Cancers in U.S.  
  • Investments in cancer care generated $598 billion of additional value for cancer patients diagnosed between 1983 and 1999.  
  • Cancer Survivors in the United States  
  • “If you had been diagnosed with chronic myeloid leukemia (CML) in 1999, chances were that you would not be alive today. Just 3 out of 10 patients survived for…  
  • Surgical biopsy for lumps in the breast was found by one study to cost 2 1/2 to 3 times more than image-guided core-needle biopsy ($698 versus $243).